Poractant alfa - Biologic Drug Details

Summary for poractant alfa

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for poractant alfa

Recent Clinical Trials for poractant alfa

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
NorthShore University HealthSystem	Phase 4
Chiesi USA, Inc.	Phase 4
VENTO GIOVANNI	Phase 2

See all poractant alfa clinical trials

Pharmacology for poractant alfa

Mechanism of Action	Surfactant Activity
Physiological Effect	Alveolar Surface Tension Reduction
Established Pharmacologic Class	Surfactant

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for poractant alfa Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for poractant alfa Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for poractant alfa Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Poractant Alfa

Introduction

Poractant alfa, marketed as Curosurf, is a pivotal biologic drug used in the treatment of Respiratory Distress Syndrome (RDS) in premature infants. This article delves into the market dynamics and financial trajectory of poractant alfa, highlighting key factors driving its market growth and the economic implications of its use.

Market Size and Growth

The global respiratory distress syndrome market, which includes poractant alfa, has been experiencing significant growth. As of 2020, the market size was valued at USD 358.7 million and is projected to reach USD 520.8 million by 2027, exhibiting a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period[3].

Driving Factors

Several factors contribute to the growth of the poractant alfa market:

Increasing Preterm Births

The rise in preterm births, particularly in developed nations, is a significant driver. Premature infants are at a higher risk of developing RDS due to their immature lungs, which produce less surfactant, a critical substance for maintaining lung function[3].

Advances in Drug Research and Development

Continuous innovations in therapeutic developments, including improvements in drug delivery mechanisms and diagnostic techniques, have positively impacted the market. Increased research funding by private investors and collaborations between pharmaceutical companies, academic institutions, and government departments have led to the development of more effective treatments for RDS[3].

Market Segmentation

The respiratory distress syndrome market is segmented based on type and application. Poractant alfa is one of the key surfactants, along with beractant and calfactant, used in the treatment of RDS. The market is further segmented into very preterm infants, moderate to late preterm infants, and others[3].

Financial Trajectory

Revenue Growth

The revenue growth of poractant alfa is closely tied to the overall growth of the RDS market. With a projected CAGR of 5.5%, the market is expected to see significant financial expansion. This growth is driven by the increasing demand for effective treatments for premature infants and the continuous investment in research and development[3].

Investment and Funding

Enhanced investment from pharmaceutical companies, academic institutions, and government departments has been crucial in driving the development of new therapeutic targets and treatment patterns. This investment not only boosts the market revenue but also ensures the availability of innovative solutions to address the needs of patients and the medical community[3].

Competitive Landscape

Poractant alfa operates within a competitive landscape that includes other surfactants like beractant and calfactant. However, its unique profile and efficacy make it a preferred choice in many clinical settings.

Surfactant Profiles

Poractant alfa is an extract of natural porcine lung surfactant, consisting of 99% polar lipids and 1% hydrophobic low molecular weight proteins (SP-B and SP-C). This composition allows it to effectively lower surface tension in the lungs, restoring adequate surface activity and improving lung compliance and gas exchange[2][4].

Clinical Efficacy and Outcomes

The clinical efficacy of poractant alfa is well-documented. Studies have shown that it significantly improves survival rates and respiratory function in preterm infants.

Survival Benefits

A study involving preterm lambs demonstrated that poractant alfa, when compared to a synthetic surfactant, provided survival benefits and improved oxygenation and ventilation efficiency. The study highlighted that lambs treated with poractant alfa had a higher survival rate after 48 hours of ventilation[5].

Clinical Guidelines

Poractant alfa is recommended by clinical guidelines, such as the 2016 European RDS guidelines, which emphasize the importance of maintaining target oxygen saturation ranges and using surfactant therapy to prevent CPAP failure in preterm infants[1][4].

Economic Implications

Cost-Effectiveness

While poractant alfa is a costly treatment, its cost-effectiveness is supported by its ability to reduce the need for prolonged ventilation and intensive care, thereby lowering overall healthcare costs. The reduction in morbidity and mortality rates among preterm infants also has long-term economic benefits[2].

Healthcare Resource Utilization

The use of poractant alfa can lead to a decrease in healthcare resource utilization, including reduced need for mechanical ventilation, lower rates of complications, and shorter hospital stays. These factors contribute to a more efficient use of healthcare resources and reduced economic burden on healthcare systems[2].

Challenges and Restraints

Regulatory and Ethical Considerations

The development and use of poractant alfa are subject to stringent regulatory and ethical considerations. Ensuring compliance with these regulations and addressing ethical concerns, such as the use of animal-derived products, can be challenging and may impact market growth[2].

Market Competition

The presence of other surfactants and ongoing research into synthetic alternatives can pose a competitive challenge to poractant alfa. However, its established efficacy and clinical preference continue to support its market position[3].

Future Outlook

Innovations and Research

Ongoing research into new surfactant formulations and delivery mechanisms is expected to further enhance the efficacy and availability of treatments for RDS. Innovations such as synthetic surfactants with SP-B and C analogs may offer additional treatment options and potentially challenge the market dominance of poractant alfa[5].

Market Expansion

The global respiratory distress syndrome market is expected to continue growing, driven by increasing preterm birth rates and advancements in therapeutic developments. Poractant alfa is likely to remain a key player in this market, given its proven clinical efficacy and established market presence[3].

Key Takeaways

• The global respiratory distress syndrome market, including poractant alfa, is projected to grow significantly, reaching USD 520.8 million by 2027.
• Increasing preterm births and advancements in drug research and development are key drivers of market growth.
• Poractant alfa's unique surfactant profile and clinical efficacy make it a preferred treatment for RDS.
• The economic implications of poractant alfa include cost-effectiveness and reduced healthcare resource utilization.
• Ongoing research and innovations in surfactant therapy are expected to shape the future market landscape.

FAQs

What is the projected market size for the respiratory distress syndrome market by 2027?

The respiratory distress syndrome market is expected to reach USD 520.8 million by 2027[3].

What is the CAGR of the respiratory distress syndrome market from 2020 to 2027?

The market is expected to exhibit a CAGR of 5.5% during the forecast period[3].

What are the main drivers of the respiratory distress syndrome market?

The main drivers include increasing preterm birth rates and advancements in drug research and development[3].

How does poractant alfa compare to other surfactants in terms of efficacy?

Poractant alfa has been shown to have significant clinical efficacy, improving survival rates and respiratory function in preterm infants, and is often preferred due to its natural surfactant composition[2][5].

What are the economic implications of using poractant alfa in the treatment of RDS?

The use of poractant alfa can reduce healthcare costs by decreasing the need for prolonged ventilation and intensive care, and by lowering morbidity and mortality rates among preterm infants[2].

Sources

1. CUROSURF® (poractant alfa) | Official HCP Website
2. Poractant alfa: Uses, Interactions, Mechanism of Action - DrugBank
3. Respiratory Distress Syndrome Market Size - Forecast To 2032
4. Surfactant profile : CUROSURF (poractant alfa)
5. New Surfactant with SP-B and C Analogs Gives Survival Benefit